Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Targets 3 Trillion Yen Sales by FY2030, Global Top-5 Oncology Spot
May 12, 2026
-
BUSINESS Lilly Japan Hits Record Sales as Mounjaro Tops 100 Billion Yen
May 12, 2026
-
ACADEMIA Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
-
BUSINESS Daiichi Sankyo Cuts FY2025 Profit Outlook on ADC Supply Plan Review
May 11, 2026
-
BUSINESS J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
-
REGULATORY Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
-
BUSINESS Gilead Files Bictegravir Plus Lenacapavir HIV Pill in Japan
April 30, 2026
-
REGULATORY MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
-
REGULATORY Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
-
BUSINESS Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
-
REGULATORY Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
-
BUSINESS Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
-
BUSINESS Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
-
BUSINESS Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
-
REGULATORY Extra Charges Likely for OTC-Like Drugs to Treat Seasonal Conditions: Minister
April 22, 2026
-
BUSINESS Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
-
BUSINESS Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
-
ORGANIZATION PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
-
BUSINESS Sobi Japan Shoots for 8 to 9-Fold Growth by 2030 on Five Approvals
April 17, 2026
-
REGULATORY Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…